Navigation Links
Codexis R&D Productivity Panels Also Used By Roche
Date:5/12/2009

REDWOOD CITY, Calif., May 12 /PRNewswire/ -- Codexis, Inc. today announced an agreement with Roche under which Roche will purchase Codex(TM) Biocatalyst Panels, a biocatalysis-based research and manufacturing productivity product.

The Codex(TM) Panels are used by pharmaceutical manufacturers to increase manufacturing productivity while reducing cost. They are based on Codexis proprietary custom biocatalysts, which can accelerate production of human therapeutics through early development of faster, lower cost, cleaner manufacturing processes. They have been used by more than 10 pharmaceutical companies worldwide.

"We are very pleased that Roche, a world leading company, will use Codexis biocatalysis technology to enhance pharmaceutical process manufacturing productivity," said Peter Seufer-Wasserthal, Ph.D., Senior Vice President, Codexis Pharmaceuticals. "Since their introduction in 2007, the Codex(TM) panels have been used to generate first kilogram quantities of a target material in weeks, instead of months. Some processes have already advanced to commercial scale. Shorter development time can contribute to lower drug development costs over many years - a priority in tight economic times."

Biocatalysts enable development of environmentally-friendly, low cost methods to produce chirally pure chemicals and have already replaced chemocatalysts in certain processes. Codexis offers panels covering major classes of enzymes that can produce a broad range of chemicals widely used by the pharmaceutical industry.

Sets of diagnostic enzyme panels are provided in a convenient 96-well format to efficiently determine if a biocatalytic solution is available for a challenging process step in the production of active pharmaceutical ingredients and intermediates needed to produce human therapeutics. Panel data is then used to rapidly develop product-specific, customized biocatalysts and biocatalytic processes for Codexis' pharmaceutical partners.

Codexis Inc. is a clean technology company. The company develops industrial biocatalysts, including enzymes and microbes. Codexis technology is used in the energy industry to enable next generation, non-food biofuels and by global pharmaceutical companies for cost-effective manufacturing of human therapeutics. Future commercial applications include carbon management, water treatment and chemical manufacturing. For more information, visit www.codexis.com.

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771


'/>"/>
SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Names Lori Giver VP Systems Biology
2. Codexis, Teva in Licensing Agreement Final
3. Codexis Names Vice President, Intellectual Property
4. Codexis, Arch Announce Expanded Collaboration
5. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
6. Codexis Names David Anton VP Bioindustrials R&D
7. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
8. Rothwell, Wolf Elected to Codexis Board
9. Codexis Opens Singapore Laboratory
10. Bruce Pasternack Elected to Codexis Board
11. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):